Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR447971 in Healthy Participants and Hidradenitis Suppurativa
NCT07629336Phase 1Recruiting
- Sponsor
- Sanofi
- Start
- May 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing SAR447971 with Placebo (2 arms). Primary endpoints: Incidence of treatment emergent adverse events at Day 42, Incidence of clinically significant abnormalities in clinical laboratory evaluations at Day 42 and 2 more. Started May 2026; status: recruiting.
02
Drugs
KT-485
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07629336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07629336.